Abstract
Extramammary Paget's disease (EMPD) is a rare, slow-growing, cutaneous adenocarcinoma that usually originates in the anogenital area and axillae outside the mammary glands. EMPD mostly progresses slowly and is often diagnosed as carcinoma in situ; however, upon becoming invasive, it promptly and frequently metastasizes to regional lymph nodes, leading to subsequent distant metastasis. To date, several chemotherapy regimens have been used to treat metastatic EMPD; however, they present limited effect and patients with distant metastasis exhibit a poor prognosis. Recently, basic and translational investigative research has elucidated factors and molecular mechanisms underlying the promotion of metastasis, which can lead to targeted therapy-based emerging treatment strategies. Here, we aim to discuss current therapies and their limitations; advancements in illustrating mechanisms promoting invasion, migration, and proliferation of EMPD tumor cells; and future therapeutic approaches for metastatic EMPD that may enhance clinical outcomes.
Original language | English |
---|---|
Article number | 38 |
Journal | Frontiers in Oncology |
Volume | 8 |
Issue number | FEB |
DOIs | |
Publication status | Published - 2018 Feb 16 |
Externally published | Yes |
Keywords
- Anti-PD-1 antibody
- CD163M2 macrophage
- CXCR4-stromal cell-derived factor-1 axis
- HER2-PI3K/ERK signaling
- Lymphangiogenesis
- Metastatic extramammary Paget's disease
- Mismatch-repair deficient
- Receptor activator of nuclear factor kappa-B ligand-RANK signaling
ASJC Scopus subject areas
- Oncology
- Cancer Research